九典制药(300705) - 九典制药投资者关系管理信息

Group 1: Financial Performance - The company's operating income for 2024 is expected to grow by 10-20% year-on-year [3] - The net profit after deducting non-recurring gains and losses is projected to increase by 30-40% year-on-year [3] - The reduction in the expense ratio is attributed to three main factors: the implementation of centralized procurement for the main product, effective control of expenses due to a marketing model transformation, and an increase in market share [2] Group 2: Product Development and Market Presence - As of July 2024, the development status of the main product, Loxoprofen Sodium Gel Patch, includes 1,300 tertiary hospitals, 1,800 secondary hospitals, 5,000 primary hospitals, and 2,000 private hospitals [2] - There are currently 12 companies that have applied to produce Loxoprofen Sodium Gel Patch, with an additional 8 companies applying for clinical trials [4] - The target consumer group for Loxoprofen Sodium Gel Patch in retail pharmacies includes patients with osteoarthritis, muscle pain, injuries, the elderly, laborers, and athletes [3] Group 3: Sales and Marketing Strategy - The company has nearly 200 sales personnel in the prescription drug segment, approximately 150 in the OTC segment, and fewer than 100 in the raw materials segment [3] - The pricing for the new anti-inflammatory and analgesic patch has not yet been determined, but it will consider existing gel patch products on the market [4] - The online and offline prices for Loxoprofen Sodium Gel Patch are generally consistent [3]